0JDI.L - Ionis Pharmaceuticals, Inc.
| Previous close | 41.06 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,642 |
| Market cap | 56.354M |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.03 |
| Earnings date | 07 Aug 2023 - 11 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksCatalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR NewswireIonis prices private placement of convertible senior notes
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ionis also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the date on which the notes ar
- PR Newswire
Ionis announces proposed private placement of convertible notes
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ionis also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day peri
ZacksIonis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Ionis announces positive donidalorsen late-stage clinical progress in HAE
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive clinical progress with donidalorsen, its late-stage investigational prophylactic therapy for hereditary angioedema (HAE). Topline two-year open-label extension (OLE) results continue to demonstrate consistent efficacy and safety, with an overall sustained mean reduction in HAE attack rates of 96% from baseline through two years across dosing groups. The company also announced that it has completed enrollment in the Phase 3 OASIS
- PR Newswire
Ionis to host 2023 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 1, 2023.
- PR Newswire
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
ZacksIonis (IONS) Q1 Earnings Surpass Estimates, Sales Match
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
ZacksHere's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 Earnings
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksIonis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Ionis reports first quarter 2023 financial results
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter of 2023. Financial results are summarized below:
ZacksAvalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on a reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval
- PR Newswire
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis' eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group. The positive results are being presented today in an Emerging Science Session at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston. ATTRv-PN is a debilitating
- PR Newswire
Ionis to hold first quarter 2023 financial results webcast
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, May 3rd at 11:30 a.m. Eastern Time to discuss its first quarter 2023 financial results.
Motley FoolCould This Rare-Disease Drug Candidate Become a Blockbuster?
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
- PR Newswire
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its partner Biogen presented new Phase 1b clinical data showing that IONIS-MAPTRx (BIIB080) reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease (AD). IONIS-MAPTRx also reduced aggregated tau pathology, as measured by positron emission tomography (PET) in all brain composites assessed. The primary endpoint of the Phase 1b study (25 weeks) an
ZacksIonis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- PR Newswire
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.
ZacksWhy Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
Ionis (Nasdaq: IONS) today announced the outcome of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a rare genetic form of ALS that leads to the loss of everyday functions and ultimately death.
PR NewswireIonis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given a Prescription Drug User Fee Act (PDUFA) action date of Dec. 22, 2023.
- Zacks
Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
ZacksIonis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
